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Abstract: Medullary thyroid carcinoma is a rare malignant tumor originating in 
parafollicular C cells. It accounts for 5 to 8% of all thyroid cancers. MTC develops in 
either sporadic (75%) or hereditary form (25%). Genetic and molecular studies have 
demonstrated the involvement of the RET proto-oncogene in hereditary MTC and, less 
often, in its sporadic form. Although a strong genotype-phenotype correlation has been 
described, wide clinical heterogeneity is observed among families with the same RET 
mutation or even in carriers of the same kindred. In recent years, several single nucleotide 
polymorphisms of the RET gene have been described in the general population as well as 
in patients with MTC. Some studies have reported associations between the presence of 
polymorphisms and development or progression of MTC. Nonetheless, other studies failed 
to demonstrate any effect of the RET variants. Differences in the genetic background of 
distinct populations or methodological approaches have been suggested as potential 
reasons for the conflicting results. Here, we review current knowledge concerning the 
molecular pathogenesis of sporadic and hereditary MTC. In particular, we analyze the role 
of RET polymorphisms in the clinical presentation and prognosis of MTC based on the 
current literature. 
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1. Molecular Basis of Medullary Thyroid Carcinoma  
Medullary thyroid carcinoma (MTC) is a rare malignant tumor originating in parafollicular C cells 
of the thyroid first described by Hazard et al. [1]. MTC accounts for 5 to 8% of all thyroid gland tumors 
and its main secretory product is calcitonin. MTC may occur sporadically, in approximately 75% of 
cases, or as part of the inherited cancer syndrome known as multiple endocrine neoplasia type 2  
(MEN 2) [2–4]. The reported 10-year mortality rate for patients with MTC varies from 13.5 to 38% [5–7]. 
The hereditary form of MTC is associated with germline mutations in the RET (RE arranged during 
Transfection) proto-oncogene, and presents as an autosomal dominant disease with a high penetrance 
and variable phenotype. RET point mutations are described mainly in exons 10, 11 and 16. However, 
less frequent mutations also occur in exons 5, 8, 13, 14 and 15 [8–13]. Hereditary MTC, also referred 
to as MEN 2, may be classified into three clinically distinct forms: multiple endocrine neoplasia   
type 2A (MEN 2A), type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC) [11,12]. 
The molecular mechanisms involved in the sporadic MTC have not yet been clarified. About   
50–80% of the cases present a somatic RET mutation M918T (Met/ATG → Thr/ACG, exon 16) [14–17]. 
However, the mutation does not appear to be uniform among the various cell subpopulations in the 
tumor or in the metastases, suggesting that sporadic MTC might be of polyclonal origin, or that the 
mutations in the RET proto-oncogene are not initial events in MTC tumorigenesis [14,16].  
This review aims at presenting an updated picture of the current knowledge on the molecular 
pathogenesis of sporadic and hereditary MTC. In particular, we critically analyze the role of RET 
polymorphisms in the clinical presentation and prognosis of MTC. 
2. The RET Proto-Oncogene 
Genetic and molecular studies have shown the contribution of the RET proto-oncogene in 
hereditary MTC and, less often, in its sporadic form. The RET gene was identified in 1985 by 
Takahashi et al. during a classical experiment of NIH 3T3 cell transfection with the high molecular 
weight DNA of human T-cell lymphoma, hence the naming of the gene as RET (RE arranged during 
Transfection) [18]. Later, studies determined the RET location in chromosome 10 and related it to the 
genesis of MEN 2A, MEN 2B and FMTC [19,20]. In 1993, for the first time, point mutations in the 
RET gene were described in patients with MEN 2A and FMTC [9,13] and in the subsequent year, a 
specific RET mutation (M918T) was associated with MEN 2B and sporadic MTC [21]. 
The RET gene encodes a receptor tyrosine-kinase, expressed in the cells derived from the neural 
crest: thyroid parathyroid cells (C cells), chromafin cells of the adrenal medulla and enteric autonomic 
plexus. Since it is a membrane receptor, the RET protein is constituted by three domains: an 
extracellular domain, a transmembrane domain and an intracellular portion containing two   
tyrosine-kinase domains (Figure 1). The extracellular domain includes regions homologous to the 
cadherin family of cell adhesion molecules and a large region rich in cysteine residues that performs 
the transduction of extracellular signals of proliferation, growth, differentiation, migration, survival 
and cell apoptosis. The intracellular domain is divided into 2 tyrosine-kinase subdomains (TK1 and 
TK2), separated by 28 aminoacids. These subdomains contain the tyrosine residues that are 
phosphorylated during receptor activation, and are involved in the activation of the signaling Int. J. Mol. Sci. 2012, 13 223 
 
intracellular pathways. RET is subject to alternative splicing of the 3′ region generating three protein 
isoforms that contain 9 (RET9), 43 (RET43) and 51 (RET51) amino acids in the carboxy-terminal tail 
downstream from glycine 1063. RET9 and RET51, consisting of 1072 and 1114 amino acids, 
respectively, are the main isoforms in vivo [22,23]. 
Figure 1.  Schematic representation of the RET receptor. The extracellular region 
comprises the cadherin and cysteine rich domain. A single transmembrane region spans  
the cell membrane. Two tyrosine kinase domains (TK1 and TK2) are located in the 
intracellular region. The corresponding exons coding for the cysteine and thyrosine kinase 
domains are indicated. 
 
3. RET Protein Activation 
The RET receptor tyrosine kinase is activated through a complex formed by the glial cell   
line-derived neurotrophic factor (GDNF) family of ligands and co-receptors. Under normal conditions, 
RET activation depends on the interaction of GFRαs (GDNF Family α Receptor) co-receptors and 
their respective ligands GFLs (GDNF Family of Ligands). The GFRα-ligand complex, together with 
the extracellular portion of RET, promotes autophosphorylation of the intracellular tyrosine   
residues [24,25]. 
The RET co-receptors are usually bound to the plasma membrane, but GFRs also occur in a soluble 
form, and can then activate RET in two distinct forms: cis or trans (Figure 2). The cis model for the 
RET activation hypothesis occurs when the GFL ligand binds to the GFRα co-receptor anchored on a Int. J. Mol. Sci. 2012, 13 224 
 
lipid platform and later this complex promotes the approach of two RET molecules through the lipid 
platform, allowing the phosphorylation of the intracellular tyrosine residues. On the other hand, the 
trans model activation suggests that the GFL may also bind to the soluble form of GFRα, stimulating 
the dimerization of RET outside the lipid platform, thus allowing its activation. Once activated, RET 
initiates the different intracellular pathways involving the regulation of processes such as 
differentiation, survival, proliferation, migration and cell chemotaxis [24,26]. 
Figure 2.  Mechanisms of ligand-mediated RET activation. (A) In the cis model   
RET activation: the glial cell line-derived neurotrophic factor (GDNF) family of ligands 
(GFL) binds to membrane glycosylphosphatidylinositol-anchored GDNF-family 
coreceptors (GFRα). The activation leads to dimerization of RET and consequently 
activation of the intracellular signaling pathways; (B) In the trans model RET activation: 
the ligand binds to the soluble form of its coreceptor (GFRα) and the ligand-GFRα 
complex brings together two inactive RET monomers. Ligand-induced activation induces 
dimerization and tyrosine phosphorylation of the RET receptor with downstream activation 
of several signal transduction pathways. 
 
The molecular mechanism by which RET mutations trigger the neoplastic process was determined 
by elegant in vitro studies performed by Santoro et al. [27]. Briefly, under normal conditions, RET is 
only activated in the presence of GFRα/GFL complex, which on binding to the RET receptor promotes 
its dimerization and auto-phosphorylation of the intracellular signaling pathways. The presence of 
mutation in the extracellular domain, as found in MEN 2A, leads to the dimerization of RET even in 
the absence of the ligand, with consequent constitutive activation of the intracellular signaling Int. J. Mol. Sci. 2012, 13 225 
 
pathways (Figure 3A). Mutations in the intracellular tyrosine-kinase domain, as found in MEN 2B, 
alter RET substrate specificity due to structural changes in this domain. Consequently, the mutated 
RET no longer needs dimerization to become active (Figure 3B) [28,29]. The activation of the RET 
protein appears to be an initial step in the oncogenic pathway in the tissues where it is expressed. 
Molecular evidence of other chromosomal abnormalities, such as loss of heterozygosity, most often at 
1p and 22q, suggest that additional cytogenetic events are probably involved [11,30]. 
Figure 3.  Characterization of RET oncogenic activation in MEN2 inherited cancer 
syndromes. (A) MEN 2A RET mutation leaves an unpaired cysteine residue in a RET 
monomer to form an aberrant intermolecular disulfide bond with another mutated 
monomer. The two mutated RET molecules are constitutively dimerized and activated;  
(B) MEN 2B RET mutation activates tyrosines in the kinase domain and alters its substrate 
specificity leading to aberrant phosphorylation of substrates of RET receptor. 
 
4. Hereditary Medullary Thyroid Carcinoma  
Approximately 25% of MTC cases occur as part of the inherited cancer syndrome of MEN 2 [7,31]. 
The MEN 2A subtype constitutes approximately 70%–80% of cases of MEN 2 and is characterized  
by the presence of MTC (95%), pheochromocytoma (30–50%) and hyperparathyroidism (HPT)   
(10–20%). The MEN 2B syndrome accounts for about 5% of the cases of MEN 2. The frequency of 
MTC is over 90%, pheochromocytoma (45%), ganglioneuromatosis (100%) and marfanoid habitus 
(65%) [11,32]. This syndrome is characterized by a single phenotype, which includes diffuse 
ganglioneuromatosis of the tongue, lips, eyes and gastrointestinal tract, long fingers and extremities, 
hyperextension of the joints and epiphyseal abnormalities. MTC in the setting of MEN 2B develops 
earlier and has a more aggressive course, occurring at a younger age compared with MTC in other 
MEN 2 subtypes [6,7]. The FMTC subtype constitutes approximately 10 to 20% of the cases of   Int. J. Mol. Sci. 2012, 13 226 
 
MEN 2 [11]. MTC is the only manifestation and thereby it is necessary to demonstrate the absence of a 
pheochromocytoma or hyperparathyroidism in two or more generations of the same family or   
the identification of related mutations to confirm that particular kindred have this syndrome. In   
these cases, the clinical presentation of MTC occurs later and the prognosis is more favorable 
(corresponding to older age at onset, often between 20 and 40 years) compared to the other forms  
of MTC [33].  
Germline RET Mutations and Disease Phenotype  
Several studies indicate a correlation among specific RET mutations (genotype) and age of onset, 
aggressiveness of MTC and the presence or absence of other endocrine neoplasms (phenotype) [11,34–36]. 
Several independent mutations in the RET at exons 5, 8, 10, 11, 13, 14, 15 and 16, have been 
established as causative of MEN 2A, MEN 2B and FMTC [8–13]. 
The majority of families with MEN 2A (more than 90%) present point mutations in the RET proto-
oncogene (missense type), involving codons located in the extracellular domain of the receptor: 609, 
611, 618 and 620 (exon 10) and 634 (exon 11). The most frequent mutations are located in codon 634, 
occurring in more than 60% of all genetically identified MTC [11,13,32,37]. Codon 634 mutations have 
been associated with the presence of pheochromocytoma and hyperparathyroidism [38], and rarely 
with CLA [39]. Nevertheless, there are a variety of phenotypic expressions in families with the same 
RET mutation [9,11,12,35,38]. Puñales et al. observed that the genotype C634R (TGC/Cys → 
CGC/Arg, exon 11) presented significantly more distant metastases at diagnosis than groups C634W 
(Cys/TGC → Trp/TGG, exon 11) and C634Y (Cys/TGC → Tyr/TAC, exon 11), thus suggesting that a 
change of specific amino acids may modify the natural development of the disease [36]. A recent study 
evaluated the RET C634W-specific neoplastic risk and age-related penetrance profiles and found that 
penetrance is high for MTC (52% by age 30, 83% by age 50 and 98% by age 70) and pheochromocytoma 
(20% by age 30, 67% by age 50 and 92% by age 70) [40]. In contrast to well-defined risk profiles for 
carriers of the codon 634 mutations, consensual clinical guidelines for RET exon 10 mutation are still 
being defined. Risk profiles and penetrance estimations in MEN 2A caused by germline RET exon 10 
mutations were recently analyzed by Frank-Raue et al. (2011) in a large multicenter study that 
included 340 subjects from 103 families. The authors observed that mutations affect mainly the 
cysteine codons 609, 611, 618 and 620 and 50% penetrance was achieved by the age of 36 years for 
MTC, by 68 years for pheochromocytoma, and by 82 years for HPT [41]. These data may facilitate 
risk assessment and genetic counseling for MTC. 
MEN 2B occurs, in approximately 95% of the cases, through a specific M918T mutation (exon 16), 
resulting in the structural change of the intracellular domain of the RET protein. In about 2–3% of 
patients with MEN 2B, the genotype A883F (GCT → TTT, exon 15) can be found [42,43]. In addition, 
a double mutation V804M/Y806C at codon 804 (Val/GTG → Met/ATG, exon 14) and 806   
(Tyr/TAC  → Cys/TGC) in the same allele was described in a patient with MEN 2B. Patients 
presenting with “atypical” MEN 2B harboring the germline double point mutation in codons 804 and 
904 (V804M and S904C) were also reported [44,45]. Mutations in codons 883 and 918 are associated 
with younger age of MTC onset and higher risk of metastases and disease-specific mortality [11,31,46]. Int. J. Mol. Sci. 2012, 13 227 
 
In FMTC, germline mutations are distributed throughout the RET gene. Approximately 86–88% of 
FMTC families have mutations in one of the 5 cysteines in the extracellular domain of the RET gene in 
exons 10 (codons 609, 611, 618, 620) and exon 11 (codon 634) [12,47]. Substitutions in the 
intracellular domain of RET in exon 13 (codon 768, 790, 791), in exon 14 (codon 804 and 844) and in 
exon 15 (codon 891) are less frequent. Interestingly, the most frequent mutation in MEN 2A, C634R, 
has not been described in FMTC families [11,47–50]. 
Based on genotype-phenotype correlation studies, the American Thyroid Association (ATA) 
developed recommendations for age of prophylactic thyroidectomy in asymptomatic RET mutation 
carriers. The different mutations are classified into four risk categories according to the aggressiveness 
of the disease (A < B < C < D). Children with mutations associated with MEN 2B phenotype (ATA 
level D risk) are at highest risk for early development of MTC and should have thyroidectomy as soon 
as possible, preferably within the first year of life. Patients with codon 634 mutations (ATA level C 
risk) are also at higher risk for development of MTC at early ages and the prophylactic total 
thyroidectomy should be carried out before 5 years of age. In patients with ATA level A and B RET 
mutations (codons 768, 790, 791, 804, 891 and 609, 611, 618, 620, 630 respectively), the risk for MTC 
is moderate and the prophylactic total thyroidectomy may be delayed beyond the age of 5 years if  
there is a less aggressive MTC family history, a normal basal stimulated serum calcitonin and normal  
neck ultrasound [51].  
5. Sporadic Medullary Thyroid Carcinoma  
Sporadic MTC generally presents as a unifocal tumor or a palpable cervical lymph node. Diagnosis 
tends to be late, generally in the fifth or sixth decade of life [52]. Lymph node metastases are detected 
in at least 50% of these patients, while distant metastases occur in ~20% of cases [53,54]. A minority 
of patients with MTC present systemic manifestations which include diarrhea, flushing, or painful 
bone metastases [6]. 
Somatic RET Mutations and Disease Phenotype 
In sporadic MTC, somatic mutation in exon 16 of the RET (M918T) has been identified in 50–80% 
of the patients [14–17]. Somatic mutations in codons 618, 603, 634, 768, 804 and 883 and partial 
deletion of the RET gene have been identified in few tumors [53,54]. The presence of a somatic RET 
mutation correlates with a worse outcome for MTC patients, not only because of the higher probability 
of persistent disease, but also because of a lower survival rate in a long-term follow up [53,54].  
The somatic RET mutations (exons 10, 11 e 16) have also been described in other endocrine tumors. 
Mutations associated with MEN 2A (codon 634 and 631) and 2B (codon 918) phenotype are also 
found in about 15–20% of sporadic pheochromocytomas [55,56]. 
6. Role of RET Polymorphisms in Medullary Thyroid Carcinoma 
Since the identification of the RET proto-oncogene as the susceptibility gene for hereditary MTC, 
major advances have been observed in studies concerning the pathogenesis of MTC and associated 
neoplasias [9,13]. However, certain aspects of the disease, such as the clinical heterogeneity observed Int. J. Mol. Sci. 2012, 13 228 
 
in individuals who have the same mutation, are not yet well understood [36,57,58]. As to sporadic 
MTC, the picture is slightly more obscure, since RET somatic mutations are not found in all   
cases [15,21,46,59] and appear not to occur uniformly among the different subpopulations of cells in 
the tumor [14,15,60]. In recent years, several authors have investigated whether the presence of variant 
sequences or polymorphisms could be associated with susceptibility for the development or 
progression of MTC. These studies have described an increased prevalence of the RET polymorphisms 
G691S (exon 11, rs1799939), L769L (exon 13, rs1800861), S836S (exon 14, rs1800862), and S904S 
(exon 15, rs1800863) in individuals with hereditary or sporadic MTC when compared with the 
population [17,57,60–62]. Below, we will discuss the main aspects related to these polymorphisms and 
susceptibility to MTC development. 
6.1. RET G691S and S904S Polymorphisms  
The non synonymous variant G691S (Gly/GGT → Ser/AGT) has been associated with developing 
sporadic MTC in two larger studies [61,63]. In an Italian population it was demonstrated that the 
frequency of G691S polymorphism was greater in patients with sporadic MTC compared to the 
controls (27.8% vs. 18.9% P = 0.029). Moreover, the authors observed that G691S polymorphism 
presents a positive significant co-segregation with S904S (SerTCC → SerTCG) polymorphism [61]. 
Additionally, Cebrian et al. (2005), have demonstrated a 1.5 to 2.5 -fold increase in the relative risk for 
the development of MTC in patients who presented polymorphisms in exons 11 (G691S), 15 (S904S) 
and 19 (STOP+388bp) [63]. These two studies postulated, through a functional assessment of   
RET transcription and splicing, that G691S could be the functional variant, but the results were 
inconclusive [61,63]. Fugazzola et al. (2008) also tested the functional activity of the RET G691S 
variant and show that the RET9-G691S protein was overrepresented when compared to RET9-WT. 
However, no transforming activity was observed [64].  
Robledo et al., in 2003, also described a strong co-segregation between polymorphisms G691S and 
S904S, reporting a strong linkage disequilibrium between these polymorphisms. Additionally, it was 
also demonstrated that haplotype G691S/S904S, in homozygosis, was more prevalent in patients   
with MEN 2A compared to the control group, suggesting a role as a gene with low penetrance for  
this variant. Furthermore, the authors observed that this variant (G691S/S904S) could modify the   
age of onset of MTC patients [57]. However, these data were not replicated in a large sample of  
European population [65].  
Although several studies have found an association between G691S/S904S polymorphisms and 
MTC, some authors did not observe a difference in the frequency of this variant between MTC patients 
and the general population [17,66–68]. Wohllk et al. analyzed 50 Chilean patients with sporadic 
tumors and 50 controls of similar ethnic origins, and showed a similar frequency of the RET 
G691S/S904S variants for cases and controls [69]. More recently, these negative results were 
replicated in Polish, Brazilian and Indian populations [17,67,68]. 
6.2. RET L769L Polymorphism  
In 2001, a study conducted by Wiench et al. reported that patients with sporadic MTC and under 
the age of 30 years presented a higher frequency of the variant L769L (LeuCTT → LeuCTG) allele Int. J. Mol. Sci. 2012, 13 229 
 
than those diagnosed between 31–45 years (36% vs. 15%, P = 0.04), suggesting that this 
polymorphism was associated with younger age at diagnosis. However, the absence of a control group 
diminished the relevance of this observation [58]. Interestingly, Magalhães et al. (2004) observed that 
a patient harboring a V804M mutation, classically associated with late-onset and lower aggressiveness 
MTC, associated with the L769L polymorphism presented clinically evident MTC at 32 years of age, 
in contrast to her asymptomatic mother, who had only the V804M mutation and had MTC diagnosed 
by fine-needle aspiration biopsy at 60 years of age. The authors suggest that polymorphism L769L of 
RET proto-oncogene may be related to younger age at the onset of disease [70]. 
An association between the presence of L769L polymorphism and F769Y mutation was reported in 
FMTC patients for Baumgartner-Parzer et al. In this study, the authors deduced from pedigree analyses 
that the F791Y mutation and L769L polymorphism are located on the same allele and speculated 
whether the presence of this polymorphism could predispose the respective allele for the occurrence of 
a F791Y de novo mutation or would modulate the disease phenotype [66].  
More recently, the presence of polymorphism L769L in the RET gene was associated with 
predisposition to the development of sporadic MTC and also younger age at onset of MTC in carriers 
of the homozygous polymorphic variant L769L. The authors also demonstrated that this variant 
modifies the structure of mRNA and could lead to changes in kinase activity and/or specificity of  
the protein [68].  
Conversely, other studies did not show an association between the L769L polymorphism and   
MTC [60,61,63,69]. Berard et al. analyzed the presence of the L769L polymorphism in patients with 
sporadic MTC and controls, and found no difference in the distribution of these polymorphisms 
between the groups analyzed [71]. Accordingly, Siqueira et al. did not observe the influence of neutral 
RET L769L variants on clinical and oncological features in individuals with hereditary or sporadic 
MTC [17]. Recently, a study performed in Indian patients also failed to demonstrate a difference in the 
frequency of this allele in MTC patients and control group [67].  
6.3. RET S836S Polymorphism  
Gimm  et al., in 1999, identified an association between the RET polymorphisms S836S   
(SerAGC → SerAGT) and sporadic MTC. The authors reported a higher frequency of the variant allele 
in the group with MTC compared with the control group (9.0 vs. 3.7% P = 0.03) [60]. These findings 
were confirmed in a Spanish population [72] 
A recent study investigated the influence of the neutral RET S836S variants on the clinical 
presentation of hereditary or sporadic MTC in a large cohort of Brazilian patients. The variant S836S 
was associated with the early onset of the disease and a higher risk for the development of lymph  
node and distant metastases (P = 0.002 and P = 0.001, respectively) in patients with hereditary or  
sporadic MTC [17].  
Other association studies, however, have failed to show differences as to the presence of S836S 
polymorphisms between patients with sporadic MTC and controls [61,63,68,69]. Wiench et al. in a 
Polish population and Berard et al. in French patients observed a similar frequency of the RET S836S 
variants for cases and controls [58,71]. Similar data were found in other populations [61,63,68,69]. 
Study performed in India did not observe significant differences in the frequency of this polymorphic Int. J. Mol. Sci. 2012, 13 230 
 
allele in the patients and control group. Interestingly, the prevalence of the RET polymorphisms in the 
Indian population was significantly higher than those observed in Germans, Italians, French, Spanish 
and Hungarians (P > 0.002) [67]. 
6.4. Other RET Variants 
Besides the variants already mentioned, other polymorphisms have also been associated with MTC. 
A study showed higher frequency of intron 14 (IVS14−24; rs2472737) polymorphism in the group 
with elevated serum calcitonin concentrations (P = 0.016) and in patients with sporadic MTC   
(P < 0.001), when compared with the control group with normal calcitonin levels. However, further 
studies are necessary to characterize a potential role of this RET sequence variant in the development 
of sporadic MTC [66]. 
Recently, two other variants of RET were identified (IVS1−126 G > T; rs2565206) and (IVS8+82  
A > G; rs3026750 and 85–86 insC; rs3482797), and associated with phenotypic variability in patients 
with mutation G533C. In this study, the authors found an association between variant IVS1–126 G > T 
and age at diagnosis of MTC. On the other hand, variant (IVS8+82 A > G; InsC 85–86) was associated 
with the presence of lymph node metastases at the time of diagnosis. Analyses in silico suggest that 
this variant may induce abnormal splicing, postulating that variant (IVS8+82 A > G; 85–86 InsC) 
could interrupt and/or create an exonic splicing site, thus leading to the synthesis of an altered   
protein [73]. In another study, a polymorphism in exon 2 (GCG → GCA), which encodes an alanine 
(A45A), occurred at a lower frequency among the cases of MTC and, according to the authors, it could 
confer a protective allele against the development of MTC [63].  
Taken together, these data point to a potential influence of RET variants in the development and 
progression of MTC. Tables 1 and 2 summarize the main findings of the studies on the role of RET 
polymorphisms in MTC. 
Table 1. Role of the RET variants in hereditary medullary thyroid cancer. 
RET variant  Author  Cases  Controls  P 
Frequency 
(cases vs. 
controls) 
Genotyping 
platform 
Conclusion Population
G691S 
(rs1799939) 
Robledo 
(2003) 
198 653  0.037 –  sequencing 
Associated with the 
presence of MTC 
in younger 
individuals. 
Spanish 
Lesueur 
(2006) 
384  –  – – Taqman  N/A  European 
Tamanah
a (2009) 
77
 a 100  0.048 0;  4  RFLP 
Underrepresented 
in G533C-arriers. 
Brazilian 
Sharma 
b 
(2011) 
51 50 NS  49;  48  sequencing  N/A  Indian 
L769L 
(rs1800861) 
Sharma 
b 
(2011) 
51 50 NS  45;  58  sequencing  N/A  Indian Int. J. Mol. Sci. 2012, 13 231 
 
Table 1. Cont. 
RET variant  Author  Cases  Controls  P 
Frequency 
(cases vs. 
controls) 
Genotyping 
platform 
Conclusion  Population
S836S 
(rs1800862) 
Tamanah
a (2009) 
77 a  100  0.008 16.9; 4  RFLP 
Over-represented 
in G533C-carriers. 
Brazilian 
Siqueira 
(2010) 
88 –  –  7.95;  – RFLP 
Associated with 
early onset and 
increased risk for 
metastatic disease. 
Brazilian 
Sharma b 
(2011) 
51 50 NS  25;  22  sequencing  N/A  Indian 
S904S 
(rs1800863) 
Lesueur 
(2006) 
384 –  –  –  Taqman  N/A  European 
Sharma b 
(2011) 
51 50 NS  25;  22  sequencing  N/A  Indian 
Tamanah
a (2009) 
77 a  100  0.048 0; 4  RFLP 
Underrepresented 
in G533C-carriers. 
Brazilian 
IVS1−126 
G>T 
(rs2565206) 
Tamanah
a (2009) 
77 a  100  0.002 1.3; 0  RFLP 
Associated with 
younger age at 
diagnosis. 
Brazilian 
IVS8+82 
A>G;  
85–86 insC 
(rs3026750) 
Tamanah
a (2009) 
77 a  –  0·019 –  RFLP 
Associated with 
lymph node 
metastases. Could 
induce abnormal 
splicing. 
Brazilian 
a Study performed in patients with RET G533C mutation; 
b The study included hereditary and sporadic MTC 
patients; N/A: no association was found. 
Table 2. Role of the RET variants in sporadic medullary thyroid cancer. 
RET variant  Author  Cases  Controls P 
Frequency 
(cases vs. 
controls) 
Genotyping 
platform 
Conclusion Population
G691S/S904S 
(rs1799939)/ 
(rs1800863) 
 
Elisei 
(2004) 
106 106  0.029 27.8;  18.8 RFLP 
Higher frequency 
in MTC patients. 
Does not 
influence RET 
mRNA 
expression 
European 
Cebrian 
a 
(2005) 
120 528  0.004 27;  18 TaqMan 
Associated with 
higher risk for 
development of 
MTC. Does not 
affect the splicing 
of RET 
British 
Wohllk 
(2005) 
50 50  NS  25;  25  sequencing  N/A
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Table 2. Cont. 
RET variant  Author  Cases  Controls P 
Frequency 
(cases vs. 
controls) 
Genotyping 
platform 
Conclusion  Population
L769L 
(rs1800861) 
Wiench 
(2001) 
116 
b –  0.04 
b 36; 15  sequencing 
Associated with 
the presence of 
MTC in younger 
individuals 
Polish 
Sromek 
(2010) 
217 420  0.039
c 48.3; 39.5
 c Sequencing
Associated with 
the presence of 
MTC in younger 
individuals (in 
homozygosis). 
Could influence 
RET mRNA 
structure 
Polish 
Berard 
(2004) 
184 174 NS  22.3;  25.9  sequencing  N/A  French 
Wohllk 
(2005) 
50 50  NS  24;  23  sequencing  N/A  Chilean 
S836S 
(rs1800862) 
Gimm 
(1999) 
50 70  0.03  9;  3.7  RFLP 
More frequent in 
MTC patients 
German-
American 
Ruiz 
(2001) 
32 250  0.04  9.3;  3.6 RFLP 
Associated with 
higher risk for 
development of 
MTC 
Spanish 
Siqueira 
(2010) 
81 80  0.01  10.5;  3.2  RFLP 
Associated with 
early onset and 
increased risk for 
metastatic disease 
Brazilian 
Berard 
(2004) 
184 174 NS  6.5;  5.2  sequencing  N/A  French 
Wohllk 
(2005) 
50 50  NS 6;  1  sequencing  N/A  Chilean 
S904S 
(rs1800863) 
Wohllk 
(2005) 
50 50  NS  27;  28  sequencing  N/A  Chilean 
Cebrian 
(2005) 
125 528  0.005 26.4;  15.5  TaqMan 
Associated with 
higher risk for 
development of 
MTC 
British 
STOP+388pb 
G>A 
(rs3026782 
Cebrian 
(2005) 
123 522  0.005 26.4;  15.5  TaqMan 
Associated with 
higher risk for 
development of 
MTC 
British 
A45A G>A 
(rs1800858) 
Cebrian 
(2005) 
126 525  0.04  21;  27.9  TaqMan 
Suggest 
protective effect 
British 
a Study did not confirm the previously described association between G691S and S904S; 
b The comparison 
was performed between patients aged below and above 30 years; 
c Frequency of heterozygous change 
L769L.N/A: no association was found. Int. J. Mol. Sci. 2012, 13 233 
 
6.5. Possible Mechanisms of Action for RET Polymorphism in Medullary Thyroid Carcinoma 
So far it is not known how polymorphisms exert their effects on the development or progression of 
MTC and the mechanistic explanation is still speculative. A quantitative study of RET mRNA levels in 
tumor tissues of individuals with MTC did not show a difference in the expression in patients with and 
without G691S/S904S polymorphism [61]. The S836S polymorphism failed to affect DNA-protein 
binding, transcript stability, or RNA splicing and editing [74]. Other hypothesis is that bases exchange 
in the DNA molecule could interrupt and/or create a splicing site, leading to the synthesis of an   
altered protein, or else, that the modified nucleotide is in a state of linkage disequilibrium with an  
as yet unknown functional variant [60,73]. It has also been proposed a specific effect of G691S 
polymorphism on RET dimerization on MEN 2A patients harboring the 634 mutation [57]. Potential 
changes on mRNA structure due to the presence of RET polymorphisms have also been evaluated. The 
simplest prediction of mRNA structure is a prediction of thermodynamic stable structure, MFE 
(minimal free energy) structure. Bioinformatics analysis showed that differences in MFE between wild 
types and mutants are <5% in the case of polymorphisms S904S and S836S and mutations Y791F and 
C634R. No effect on MFE was visible also in the combination of C634R and L769L polymorphism. 
However, the difference was noticeable in the case of exon 13. The L769L variant reduces the energy 
of the wild type by 17% and the mutant Y791F by 7%, leading the authors to conclude that the L769L 
polymorphism reduces the MFE of small RET mRNA [68]. Finally, in silico analysis revealed that the 
IVS1−126 G>T genetic variant creates a new binding site for NFAT transcription factor (nuclear 
factor of activated T-cells) [75]. The NFAT family of proteins has been found to be involved in cell 
cycle regulation, cell differentiation, cell survival, angiogenesis, tumor cell invasion, and metastasis [76], 
which may explain the association of this variant with disease progression [73]. 
7. Conclusion 
In summary, since the recognition of the RET proto-oncogene as the susceptibility gene for 
hereditary MTC several decades ago, advances have taken place in understanding pathogenesis of 
MTC and associated neoplasias. Nevertheless, certain aspects of the disease, such as the clinical 
heterogeneity seen in individuals harboring the same mutation have not yet been well understood. 
Polymorphisms in the RET gene are commonly associated with MTC and may partially explain the 
large clinical heterogeneity observed in MEN 2A patients. An entire set of data obtained from clinical 
studies indicates a potential role of RET polymorphisms in the development of sporadic MTC. 
However, in contrast, several others failed to demonstrate any association between these RET variants 
and MTC development or disease progression. Although differences in ethnic background or 
methodological flaws might be potential causes for the different results described, the mechanism 
underlying the positive associations is still lacking which stimulates further controversy. Since the 
contribution of a single variant to a disease is determined by the prevalence of the implicated allele and 
the magnitude of the association with the condition, the results summarized here might indicate the 
need for large multicenter studies to confirm or rule out a role of these variants as a cause or modifying 
agent in this rare disease. Int. J. Mol. Sci. 2012, 13 234 
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